Sartorius Aktiengesellschaft

Research Sartorius Aktiengesellschaft (0NIQ) on Bullrun: valuation model: 10.3% overvalued, P/E 29.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker0NIQ
ExchangeLSE
CountryGermany
SectorTechnology
IndustryScientific & Technical Instruments
CurrencyEUR
Valuation signal10.3% overvalued
P/E29.0
Financial periodQ1 2026
RevenueEUR 899.10M
Net incomeEUR 56.20M
Free cash flowEUR 111.20M
Gross margin46.1%

Valuation Snapshot

Bullrun's latest valuation model marks Sartorius Aktiengesellschaft as 10.3% overvalued; P/E is 29.0.

About Sartorius Aktiengesellschaft

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems;

Frequently asked questions

Is Sartorius Aktiengesellschaft overvalued or undervalued?

Bullrun's valuation model currently marks Sartorius Aktiengesellschaft as 10.3% overvalued.

What is Sartorius Aktiengesellschaft's P/E ratio?

Sartorius Aktiengesellschaft's price-to-earnings (P/E) ratio is 29.0.